Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patientsVassili Soumelis, Yongjun Liu, Laurence Huang et al.|Blood|2001Cited by 389
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trialJean‐Michel Molina, Juergen Rockstroh, Kathleen Squires et al.|The Lancet HIV|2018Cited by 145
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trialsChloe Orkin, Christine Katlama, Jean‐Michel Molina et al.|The Lancet HIV|2023Cited by 31